MOTS-c
Also known as · Mitochondrial-derived peptide · 12S rRNA sORF product · Mitochondrial ORF of 12S
- EvidencePreclinical
- CategoryMitochondrial / longevity
- RoutesubQ / IM
- Half-lifeNot established in humans
- Form
- Lyophilized powder
- Purity
- ≥98% (HPLC)
- Molecular formula
- C101H152N28O22S2
- Molecular weight
- 2174.6 g/mol
- CAS number
- 1627580-64-6
- Sequence
- MRWQEMGYIFYPRKLR
- COA
- Available on request
In stock
Request pricing
Contact us for current pricing and bulk quotes.
Reserve vial →For research use only. Not for human consumption. Buyers must be affiliated with a research institution.
01 / Research summary
What the literature reports
MOTS-c is a 16-amino-acid peptide encoded not by nuclear DNA but by a short open reading frame within the mitochondrial 12S rRNA gene. It is one of the founding members of the mitochondrial-derived peptide family.
Cellaire classifies MOTS-c as preclinical evidence. The founding Lee et al. paper (Cell Metabolism 2015) established the 51-bp sORF, cytoplasmic translation, conservation across 14 species, and detection of the peptide in rodent tissues and human plasma. Reported metabolic and insulin-sensitizing effects come almost entirely from mouse and rat models.
02 / Reconstitution
Reconstitution reference
Illustrative unit math for a 10 mg vial reconstituted with 2 mL bacteriostatic water. This is not a dose recommendation.
03 / Overview
Molecular overview
MOTS-c (Mitochondrial Open-reading-frame of the Twelve S rRNA type-c) is the peptide MRWQEMGYIFYPRKLR, translated from a 51-base-pair sORF within the mitochondrial 12S ribosomal RNA gene.
It is the first well-characterized mitochondrial-derived peptide with metabolic activity in mammals. Circulating levels vary with exercise: skeletal-muscle MOTS-c rises roughly 11.9-fold after acute exercise in humans.
Preclinical work reports AMPK activation, insulin sensitization, glucose disposal in muscle, and anti-inflammatory activity in mouse models of obesity, diabetes, and aging.
MOTS-c is not FDA-approved for any indication and is on the FDA Category 2 bulk substances review list.
04 / References